Vienna, Austria, January 27th: EUCODIS Bioscience is glad to announce that it has teamed up with Tube Pharmaceuticals to bring the production of tubulysins to a commercial level. Tube Pharmaceuticals and EUCODIS now jointly produce and commercialize tubulysin A and B and other variants of this cytotoxic compound.
Tubulysins are isolated from the culture broth of strains of Archangium gephyra and Angiococcus disciformis, both members of a Gram negative, soil-dwelling group of bacteria known as myxobacteria. The production process has been up-scaled and tubulysin A and B are now produced by EUCODIS Bioscience.
The compounds bind to tubulin, the basic protein of microtubules, which play a structural role in the cell’s cytoskeleton and a functional role in mitosis. Tubulysin binding causes microtubules to depolymerize, leading to break-up of the cytoskeleton and driving the cell into apoptosis.
Tubulysins, and their synthetic derivatives, can be covalently conjugated to a wide variety of carrier molecules including antibodies, peptides or nanoparticles, and thereby offer the potential to target many types of cells and tissues. In certain drug-resistant cell lines, such as resistant ovarian cancer, tubulysin shows a greater potency profile than other toxins.
About Tube Pharmaceuticals GmBH: www.tubepharma.de
Tube Pharmaceuticals GmbH, a Vienna-based start-up formed in 2011, is commercializing a natural products platform having its foundation in the discovery of tubulysin molecules. Tubulysins, microtubule- disrupting agents and their synthetic derivatives, can be covalently conjugated to a wide variety of carrier molecules, and thereby offer the potential to target many types of cells and tissues. Tube is developing a polymer-tubulysin conjugate for solid tumors and has licensed the toxin for use in other conjugate therapeutics to selected partners.
Tubulin skeleton of cancer cells disrupted by tubulysins
Picture kindly provided by Prof. G. Hoefle, Braunschweig, Germany